Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test could spare thousands from unneeded colonoscopies

NCT ID NCT07237984

Diagnosis Sponsor: Nordsjaellands Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 2 times

Summary

This study tests a new blood test that looks for special molecules called ofCS, which reappear in most colorectal cancers. Researchers will collect blood and stool samples from 2000 people scheduled for a colonoscopy in Denmark. The goal is to see if combining the blood test with existing stool tests can more accurately identify who truly needs a colonoscopy, reducing unnecessary procedures while still catching cancers early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood test for oncofetal chondroitin sulfate-modified proteoglycans (ofCS)
What this could lead to
If successful, this blood test could help doctors decide who really needs a colonoscopy, catching cancers early while avoiding many unnecessary procedures.
What could go wrong
This is an early-stage study with 2000 people in Denmark. The test may not work as well in larger, more diverse groups, and it is not yet proven to reduce harm or save lives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

People living within the Capital Region of Denmark referred to a screening or colorectal cancer diagnostic pathway colonoscopy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients planned to undergo a colonoscopy either as part of the colorectal cancer screening programme due to a positive FIT or within a 'cancer patient pathway' for CRC at one of the study sites. * Able to speak Danish, English, or other languages with sufficient interpretation provided by relatives. * Able to give informed consent Exclusion Criteria: * Patients previously included in the study * Patients known to be pregnant (pregnancy test not required) * Non-resident in Denmark.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal adenoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal adenoma colorectal cancer colorectal neoplasm inflammatory bowel disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal adenoma Colorectal cancer Inflammatory bowel disease (IBD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Copenhagen University Hospital - Amager-Hvidovre

    RECRUITING

    Hvidovre, 2650, Denmark

  • Copenhagen University Hospital - North Zealand

    RECRUITING

    Hillerød, 3400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.